Back to Results
First PageMeta Content
Intermittent claudication / Phosphodiesterase / Peripheral vascular disease / Claudication / Antiplatelet drug / Lactams / Vasodilators / Circulatory system / Angiology / Medicine


Kowa Announces the Efficacy and Safety of a Novel Phosphodiesterase 3 Inhibitor K-134 for the Treatment of Intermittent Claudication in AHA 2011
Add to Reading List

Document Date: 2011-11-09 22:08:47

Open Document

File Size: 40,96 KB

Share Result on Facebook

City

TOKYO / Orlando / Nagoya / /

Company

Kowa Company Ltd. / /

Country

Japan / United States / /

Event

FDA Phase / /

MedicalCondition

Intermittent Claudication / peripheral arterial disease / Peripheral Artery Disease / /

Organization

American Heart Association / /

Person

Yoshihiro Miwa / /

Position

President & CEO / /

Product

Japan / US / K-134 / /

ProvinceOrState

Florida / /

Technology

drug discovery / /

SocialTag